Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Merck announced today that data from the pivotal Phase III study with GARDASIL in males were published in the February 3 issue of the New England Journal of Medicine.

3 Feb 2011

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Eli Lilly and Company and Bristol-Myers Squibb Company announced today that they have stopped enrollment in one of their two global Phase III studies evaluating necitumumab, an investigational anti-cancer agent, as a first-line treatment for advanced non-small cell lung cancer (NSCLC).

3 Feb 2011

Exposure to infections in early childhood can protect child from eczema later in life: Study

Exposure to worm infections in the womb may protect a newborn infant from developing eczema, a study funded by the Wellcome Trust suggests. A large trial in Uganda showed that treating a pregnant woman for worm infections increased her child's chances of developing the allergic skin disease.

29 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Ligand announces acquisition of CyDex Pharmaceuticals

Ligand Pharmaceuticals Incorporated today announced it has acquired privately held CyDex Pharmaceuticals, for a combination of cash and contingent payments.

26 Jan 2011

Evaluating patients for genetic variations impacts adherence to antiviral therapy

In two recent studies, researchers have identified two functional variants in the inosine triphosphatase (ITPA) gene that protect patients with hepatitis C virus (HCV) against anemia brought on by antiviral treatment. The ability to identify those patients protected against treatment-induced anemia will ensure completion of antiviral therapy and successful elimination of the virus.

25 Jan 2011

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

GlaxoSmithKline (GSK) has become aware of a United States market recall of all lots of alcohol prep pads, swabs and swabsticks manufactured by the Triad Group and marketed under various brand names. The Triad Group recall has been initiated due to concerns about potential microbial contamination of the alcohol products with Bacillus cereus that could potentially lead to life-threatening infections.

25 Jan 2011

Wrigley launches school-based program to improve health, nutrition in school-age children

The Wm. Wrigley Jr. Company Foundation today announced the launch of a two-year, $3 million school health partnership with Save the Children. The initiative will be activated in six countries across the world, aimed at improving the health and nutrition of more than 273,000 school-age children in disadvantaged communities.

25 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Study evaluates Masimo SpHb's accuracy in monitoring low hemoglobin levels

Masimo announced today that a new study demonstrating the clinical accuracy and value of its noninvasive and continuous hemoglobin monitoring technology breakthrough was presented this week at the Society of Critical Care Medicine Annual Critical Care Congress in San Diego.

21 Jan 2011

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

Vertex Pharmaceuticals Incorporated announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for telaprevir and granted the company's request for six-month Priority Review. Telaprevir is Vertex's lead medicine in development for people with genotype 1 chronic hepatitis C.

20 Jan 2011

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Allos Therapeutics, Inc. today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

20 Jan 2011

Dextran-coated onto iron oxide nanoparticles can detect cholera toxin: Study

A complex sugar may someday become one of the most effective weapons to stop the spread of cholera, a disease that has claimed thousands of lives in Haiti since the devastating earthquake last year.

19 Jan 2011

Study demonstrates clinical accuracy of Masimo's noninvasive, continuous hemoglobin monitoring technology

Masimo announced today that a new clinical study demonstrating the clinical accuracy of its noninvasive and continuous hemoglobin (SpHb®) monitoring technology breakthrough was presented last week at the Society for Technology in Anesthesia (STA) Annual Meeting.

19 Jan 2011

FDA grants CASMED 510(k) clearance for expanded labeling of FORE-SIGHT Absolute Tissue Oximeter

CAS Medical Systems, Inc. today announced receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for expanded labeling of its FORE-SIGHT® Absolute Tissue Oximeter to monitor skeletal muscle of infants, children and adolescents weighing between 5 and 50 kg.

18 Jan 2011

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec patients with serious blood cancers (intermediate-2 and high-risk myelodysplastic syndrome and acute myeloid leukemia) now have publicly funded access to a new innovative therapy, VIDAZA® (azacitidine). Following a priority review and subsequent positive recommendation from the Conseil du medicament, patients now have the potential to significantly extend survival.

18 Jan 2011

First 6 months of exclusive breast feeding: Child health experts question recommendation

Current guidance advising mothers in the UK to exclusively breast feed for the first six months of their baby's life is being questioned by child health experts on bmj.com today.

14 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Merck today announced that the New Drug Application (NDA) for the Company's investigational extended-release formulation of JANUMET for type 2 diabetes has been accepted for standard review by the U.S. Food and Drug Administration (FDA). The Company is also moving forward as planned with regulatory filings in countries outside the United States.

12 Jan 2011

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Researchers at Nationwide Children's Hospital report a gene therapy strategy that improves the condition of a mouse model of an inherited blood disorder, Beta Thalassemia.

11 Jan 2011

Anemia News and Research

Further Reading

Merck announces publication of GARDASIL pivotal Phase III study data in NEJM

Enrollment stopped in one of two global necitumumab Phase III studies in NSCLC

Exposure to infections in early childhood can protect child from eczema later in life: Study

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Ligand announces acquisition of CyDex Pharmaceuticals

Evaluating patients for genetic variations impacts adherence to antiviral therapy

Triad alcohol prep pads with ARIXTRA Starter Kits not to be used

Wrigley launches school-based program to improve health, nutrition in school-age children

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Study evaluates Masimo SpHb's accuracy in monitoring low hemoglobin levels

FDA accepts Vertex's telaprevir NDA for six-month Priority Review

FOLOTYN Phase 2 peripheral T-cell lymphoma study results published in Journal of Clinical Oncology

Dextran-coated onto iron oxide nanoparticles can detect cholera toxin: Study

Study demonstrates clinical accuracy of Masimo's noninvasive, continuous hemoglobin monitoring technology

FDA grants CASMED 510(k) clearance for expanded labeling of FORE-SIGHT Absolute Tissue Oximeter

Quebec reimburses VIDAZA for treatment of blood cancer

First 6 months of exclusive breast feeding: Child health experts question recommendation

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FDA accepts Merck's JANUMET extended-release formulation NDA for type 2 diabetes

Researchers report gene therapy strategy that improves Beta Thalassemia in mice model

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News